Monday, 16 March 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 16 March 2026
News

12 drugs in PBS limbo pileup

Posted 16 March 2026 AM

Twelve drugs that secured a recommendation at the PBAC’s November 2025 meeting have since stalled in the PBS listing process with the submissions for reimbursement marked inactive.

The list includes big names such as Biogen’s Skyclarys – the first treatment for the rare genetic disease Freiedreich ataxia and Apellis’ Syfovre, which was the only TGA approved treatment for geographic atrophy up until recently when Astellas Pharma’s Izervay was approved.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.